Metabolic Diversity in Tumors Assessed by 18F-FDG PET/CT as a Prognostic Indicator in Diffuse Large B-Cell Lymphoma - Takeaways - MDSpire

Metabolic Diversity in Tumors Assessed by 18F-FDG PET/CT as a Prognostic Indicator in Diffuse Large B-Cell Lymphoma

  • By

  • Wenchong Xin

  • Fei Wang

  • Luo Lu

  • Haoyu Zang

  • Bai He

  • Weiying Gu

  • Yuetao Wang

  • November 24, 2025

  • 0 min

Share

  • 1

    Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive non-Hodgkin’s lymphoma, significantly impacting patient survival rates.

  • 2

    Standard R-CHOP treatment improves outcomes, but relapsed or refractory DLBCL patients face poor prognosis with limited treatment options.

  • 3

    18F-FDG PET/CT is crucial for assessing tumor burden and treatment response in DLBCL, but traditional metrics may not fully predict prognosis.

  • 4

    Tumor metabolic heterogeneity (MH) assessed by 18F-FDG PET/CT may enhance prognostic stratification for DLBCL patients.

  • 5

    The study aims to evaluate the prognostic significance of tumor MH and develop a comprehensive prediction model for DLBCL outcomes.

Original Source(s)

Metabolic Diversity in Tumors Assessed by 18F-FDG PET/CT as a Prognostic Indicator in Diffuse Large B-Cell Lymphoma

  • by Wenchong Xin, Fei Wang, Luo Lu, Haoyu Zang, Bai He, Weiying Gu, Yuetao Wang

  • November 24, 2025

Related Content

High-grade astrocytoma with piloid features: a case report of comprehensive management

Ultra-high-sensitivity next-generation sequencing–based MRD predicts outcome in intensively treated older patients with acute myeloid leukemia: results from the ALFA-1200 cohort

Case Report: Synovial sarcoma with diffuse myxoid stroma and complete absence of epithelial differentiation in the extremity